Anavex Life Sciences Corp (AVXL)

[blu_1]

By utilizing an adaptive design in our current ANAVEX 2-73 Phase 2a study, the treatment was finely adapted to the *patient’s* response, sparing patients from unnecessary side effects and safeguarding patients’ well-being, as evidenced by a high retention rate in this maximum tolerated dose (MTD) study,” said Christopher U. Missling...

In the above quote, was Missling talking about individual patients in the trial or about the patient group as a whole? Was he referring to "patient's" as a cohort group or as individuals? English is his second language and I think that sometimes results in ambiguity and confusion.

Please provide the source of the above quote. Who was quoting Missling? Anavex PR dept, FierceBiotech, or someone else?